Physician profile
Gregory A Greco
NPI 1083764187
$16,381.88
in general payments reported to CMS, 2019-2025
17 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2021: $562 · 2022: $710 · 2023: $990 · 2024: $1,417 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $3,116 · Long Term Medical Supply Or Device Loan: $408 · Travel and Lodging: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,640.00 |
| Food and Beverage | $3,115.61 |
| Long Term Medical Supply Or Device Loan | $407.58 |
| Travel and Lodging | $339.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $11,463.45 | 2025 | |
| Abbvie INC. | $2,012.01 | 2023-2025 | |
| Allergan, INC. | $805.89 | 2019-2022 | |
| Integra Lifesciences Corporation | $567.00 | 2023-2025 | Acell, Integra, Surgimend |
| Davol INC. | $256.69 | 2021-2022 | |
| Tela Bio, INC. | $196.63 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Kerecis Limited | $147.78 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| W. L. Gore & Associates, INC. | $146.57 | 2019 | |
| Rti Surgical, INC | $136.45 | 2022 | |
| Derma Sciences, INC. | $133.30 | 2019 | |
| Medtronic, INC. | $127.50 | 2022 | |
| Innocoll Pharmaceuticals Limited | $97.77 | 2022 | |
| Sientra, INC. | $87.34 | 2021-2022 | |
| Merz North America, INC. | $75.00 | 2022 | |
| Motiva USA, LLC | $73.60 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mindray Ds USA, INC. | $42.63 | 2023-2024 | Te X, Te7 Max |
| Celgene Corporation | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Greco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.